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Abstract
Background: Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of
advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed
investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim of the
NEOMUN investigator initiated trial (EudraCT-Number: 2017–000105-20; ClinicalTrials.gov Identifier: NCT03197467) is
to assess feasibility and safety of pre-surgical anti PD-1 treatment in order to improve long term survival.
Methods: The study is designed as an open-label, single arm, prospective, monocenter, phase II study including 30
patients with NSCLC stage II/IIIA suitable for curative intent surgery. Investigational drug is Pembrolizumab. After 2
cycles of immunotherapy (à 200 mg q3w i.v.), tumor resection with lobectomy or bilobectomy will be performed.
Primary objectives are to assess the feasibility and safety of a neoadjuvant immunotherapy and to assess antitumor
activity of Pembrolizumab with regard to clinical and pathological tumor response. Secondary objective is disease
free and overall survival. Exploratory objective is to analyze potential predictive biomarkers and to evaluate the
therapeutic efficacy of Pembrolizumab by extended immune cell and cytokine analysis of tumor tissue.
The study protocol was approved by the local ethics committee and the federal authority. Start of patient
enrollment is scheduled for June 2018.
Discussion: The NEOMUN trial will be one of the first clinical trials investigating a multimodal treatment strategy
including neoadjuvant immunotherapy using Pembrolizumab as an investigational drug. Assessing the safety and
therapeutic potential of neoadjuvant immunotherapy in connection with lung surgery will be of great interest for
thoracic surgeons.
Trial registration: Prospectively, the NEOMUN study has been registered on www.clinicaltrials.gov; NCT03197467
(first post: June 23rd, 2017).
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Background
Lung cancer is one of the leading causes of death world-
wide with approximately 230.000 new diagnoses per year
in the United States and 410.000 in Europe [1, 2]. Non-
small cell histology (NSCLC) accounts for 80% of all lung
cancer patients [3]. Less than two thirds of all patients
with a newly diagnosed NSCLC have the chance of a cura-
tive treatment. Only about 25% are diagnosed in a very
early stage (stages IA to IB) [4, 5]. In these early stages,
5-year-survival ranges from 60 to 80% after radical surgi-
cal treatment [6]. Patients with locally advanced (T2-T4)
tumors or limited nodal disease (N1, unilevel N2) do
profit from a multimodal therapy including surgery
followed by adjuvant cisplatin duplet chemotherapy.
Nevertheless, survival of patients in stages IIA and IIB
with nodal tumor involvement (N1) is estimated be-
tween 55 and 35% at five years and is even worse (15 to
40%) for patients with locally resectable tumors but
limited nodal N2-disease. Following complete micro-
scopic resection (R0), adjuvant chemotherapy may im-
prove survival benefit of only approximately 5% [7, 8].
Until now, the recommendation for adjuvant treatment
in resectable stages IIA to IIIA NSCLC is based on a
meta-analysis of few studies that have been conducted
up to 20 years ago [9].
In contrast to standard cisplatin based chemotherapy,
novel drugs modulating the patient’s immune-system
unleashing the anti-tumor immunity have been imple-
mented into modern treatment strategies. Special interest
has been raised by so-called regulatory immune-inhibitory
pathways including the programmed death-receptor 1
(PD-1) and its ligand (PD-L1). Besides others, these mole-
cules are expressed on the tumor cell surface (PD-L1) or
the patients activated T-cells (PD-1). Ligation of PD1/
PD-L1 suppresses activated T-cells, thus resulting in im-
paired anti-tumor immunity [10, 11].
Antibodies blocking the ligation of PD-1/PD-L1 have
been investigated in recent clinical trials in NSCLC
stage IV patients (KEYNOTE-trials). Treatment of
selected patients (PD-L1 expression on at least 50% of
the tumor-cells, no EGF-receptor mutation or ALK-
translocation) with a monoclonal humanized antibody
against PD-1 (Pembrolizumab, KEYTRUDA©) corre-
lated with an increased progression-free survival (median
10.3months vs. 6.0 months, p < 0.001) and an overall sur-
vival of 80.2% at 6months compared to 72.4% in patients
receiving standard chemotherapy (p < 0.005). These
findings resulted in the recent approval of Pembrolizu-
mab as first line-treatment for patients with a PD-L1
expression > 50%. Nevertheless, the KEYNOTE study
population consisted of patients with advanced or
metastatic NSCLC [10].
The feasibility and safety of neoadjuvant immunother-
apy prior to tumor resection has been proven in a recently
published study by Forde et al. Preliminary data shows en-
couraging results in clinical and pathological response
evaluation [12]. Based on these experiences, aim of the
NEOMUN investigator initiated trial (NCT03197467;
EudraCT No.: 2017–000105-20) is to assess feasibility and
safety of neoadjuvant anti PD-1 immunotherapy followed
by curative intent surgery. Monitoring clinical and radio-
logical response will be supplemented by a translational
interdisciplinary research program. Assessing the in-
duction of tumor specific immunity will help to more
intensively explore potential immunotherapy-associated
changes in the tumor and its microenvironment.
Methods
Trial design
The study is designed as a mono-center, open-label, sin-
gle arm, prospective, phase II study. Pembrolizumab
(KEYTRUDA®) will be administered in a neoadjuvant
setting to patients with resectable NSCLC stage II/IIIA
who are eligible for curative intent surgery. The percent-
age of patients reaching the surgical therapy following
neoadjuvant immunotherapy should exceed 80%.
Objectives of the study
Primary Objectives are to assess the feasibility and safety
of a neoadjuvant application of Pembrolizumab and to
evaluate the effectivity of an anti-PD1-treatment on clin-
ical and pathologic tumor response.
Secondary Objective is to assess the impact of neoadju-
vant Pembrolizumab application on patient disease free-
and overall survival.
Exploratory objective is the translational assessment of
treated and untreated tumors (e.g. inflammatory infil-
trates in and around the resected tumor, serum- and
tumor tissue cytokine concentrations, multi-OMICS
tissue analysis; see section “Translational research”) in
order to generate a hypothesis on potential biomarkers
predicting the efficacy of Pembrolizumab.
Endpoints of the study
Primary endpoints are to evaluate the frequency and sever-
ity of adverse events including peri- and post-operative
complications (grade 2–4 AEs according to NCI-CTCAE
V4.03) in all participants. Immunotherapy-associated tumor
response will be assessed by
– radiological change (Δ tumor size / lymph node
size), according to RECIST [13] and iRECIST*
([14]).
– functional (PET-activity (standardized uptake value
[SUV] [15]) and
– pathological response parameters (regression
grading according to Junker criteria [16])
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*Immunotherapy-trials described unique patterns of
tumor response (pseudoprogression). A subset of pa-
tients meeting RECIST 1.1 criteria for disease progres-
sion (in size or number of lesions) showed delayed but
durable responses to therapy by time. iRECIST therefore
widens RECIST to immune-related response criteria,
notably iUPD (unconfirmed progressive disease). A new
or growing lesion is then defined as iUPD until definite
progression is confirmed over time.
Secondary endpoints are disease free- and overall survival
Sample size calculation
Targeted sample size is 30 patients. The rationale for the
sample size is based on ethical, clinical and scientific
considerations. The neoadjuvant treatment approach
with an immune checkpoint inhibitor is experimental
with only limited data on safety and feasibility available
until today. Therefore, only a small number of patients
should be subjected to this experimental treatment. The
sample size should allow the generation of statistically
meaningful evidence for feasibility and safety to permit
the decision to further develop this treatment strategy.
With a sample size of N = 30 and assuming that the
number of events follows a binomial distribution B
(30,p), events with an incidence rate p > 9.5% will be
observed at least once with a 95% probability. This
observation limit will exclude individual Pembrolizumab
related SAEs but covers most of the historical reference
events/rates (e.g. more frequently reported SAE/AE in
Pembrolizumab monotherapy trials [e.g. pneumonia,
pleural effusion, pneumonitis, dyspnea, pulmonary embol-
ism], reported pathological and radiological response rates
to Pembrolizumab treatment). The reported frequency of
these events has been taken into account to calculate the
95%-confidence interval (under a sample size of n = 30)
using the Clopper-Pearson-Method [17, 18].
Patient selection/screening
All patients (male and female, age: 18 years and older,
ECOG performance status 0–1) with clinically suspected
lung cancer that are scheduled for surgical cancer ther-
apy at the Thoraxklinik Heidelberg will be screened for
eligibility to participate in the NEOMUN-trial. Baseline
inclusion criteria are non-small cell histology in clinical
stages IIA to IIIA.
The decision for radical surgical therapy as an integral
part of the therapy must be agreed on the oncological
interdisciplinary tumor board. Each possible candidate is
simultaneously re-evaluated by the principal investigator
or authorized medical staff. Only patients with adequate
cardiopulmonary function according to current treatment
guidelines will be counted eligible for trial inclusion [19].
Further inclusion criteria are displayed in Table 1.
Timeline
All patients with histologically proven NSCLC in stages
IIA to IIIA who are likely to meet all of the inclusion cri-
teria and none of the exclusion criteria, may be included
into the trial between day − 28 and 0. The treatment period
will start after the first administration of Pembrolizumab
(day 1). The second application is planned at day 21.
Table 1 Inclusion and exclusion criteria for participation in the NEOMUN trial
Key inclusion criteria: Key exclusion criteria:
Age≥ 18 years, ECOG status 0–1 Active autoimmune disease
History of chronic systemic steroid therapy
Histologically confirmed NSCLC Anticancer treatment < 30 days
Clinical stage IIA-IIIA according to the TNM classification, 7th edition [20]:
(stages IIIA1–3* Robinson classification [36])
Clinical T4 tumor (according to the 7th edition of the TNM-system [20])
Staging by PET/CT and brain magnetic resonance imaging (MRI) Status post or current pneumonitis that required steroids
At least 1 measurable lesion according to RECIST 1.1 [13] Monoclonal antibody-treatment (< 30 days)
Live vaccination (< 30 days)
Targeted small molecule therapy
Previous treatment with checkpoint inhibitors
Adequate bone marrow function, liver and renal function Symptomatic acute cardiovascular or cerebrovascular disease
Evidence of interstitial lung disease
Adequate lung and cardiac function for intended lung resection
according to German S3 guideline [37]
Psychiatric illness that might affect the patient’s ability to
understand the demands of the clinical trial
Note: subjects of childbearing potential must use an adequate
method of contraception
History of allogeneic tissue/solid organ transplant
Hypersensitivity to Pembrolizumab
Known active TBC, HBV, HCV or HIV infection
A full list of inclusion/exclusion criteria on https://clinicaltrials.gov/ct2/show/NCT03197467 Protocol Version 3.0, October 16th, 2017
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During the pre-surgical period between day 42 to 50, a sec-
ond PET-scan will be performed for radiological baseline
assessment followed by curative intent surgery (day 50+).
Adjuvant standard chemo- and/or radiotherapy will be
administered according to the current guidelines. Each
patient will be followed up 24 months after completion
of the entire tumor therapy (Fig. 1).
Procedures
Clinical staging/histological assessment
A contrast enhanced thoracic computed tomography
(CT) will initially be performed in all patients that are
screened for the trial. Distant metastatic disease will
be radiologically ruled out using a diagnostic positron-
emission-tomography-scan (PET) of the whole body
and magnetic resonance imaging of the brain (MRI).
All patients receive rigid and flexible bronchoscopy to
evaluate the endobronchial anatomy. The mediastinum
is examined using endobronchial ultrasound. Enlarged
(> 1 cm in conventional chest CT) or PET positive medi-
astinal lymph nodes will be clarified by EBUS-guided bi-
opsy. If malignancy cannot be ruled out, mediastinoscopy
will be performed. Histological confirmation of NSCLC
will be provided by either transbronchial biopsy (TBB),
transbronchial needle aspiration (TBNA) or transtho-
racic biopsy (ultrasound-guided or computed tomog-
raphy guided).
Clinical staging will be proceeded in accordance to the
actual TNM-classification. As defined by protocol, pa-
tients that meet the stage inclusion criteria according the
7th edition will be screened for eligibility to participate
(Stages IIA - IIIA). Nevertheless, TNM-classification from
the 7th and the actual valid 8th edition will both be
provided [5, 20] .
Neoadjuvant immunotherapy
Investigational drug is intravenous Pembrolizumab at a
fixed dose of 200 mg every three weeks ((q3w), 21 days)
for 2 cycles (day 0, day 21).
Surgery
Following neoadjuvant immunotherapy, curative intent
radical surgery will be performed in each patient meet-
ing eligibility criteria. Thoracic surgery is no study pro-
cedure. Depending on individual patient factors (e.g.
body weight, height, thoracic anatomy and tumor loca-
tion), access into the chest cavity will be provided either
by open surgery (anterolateral horizontal incision over
the 3rd to 5th intercostal space) or endoscopic surgery
(video-assisted thoracoscopy; one to three individually
placed small utility incisions triangulated over the lateral
chest wall). The study investigators will plan the patients
for at least anatomical pulmonary lobectomy including
systematic complete hilar and mediastinal lymphadenec-
tomy, as systematic nodal dissection is an integral part
Fig. 1 Timeline and summarized study protocolV1, V2: First and second administration of Pembrolizumab at day 0 and day (d) 21. Q3w: every
three weeks; EOT: end of treatment; RT: radiotherapy; PET: positron emission tomography; iv: intravenous; d: day; cMRI: cranium Magnet
Resonance Tomography
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of the surgical procedure to accurately assess the pa-
tients correct regional nodal status [21].
Adjuvant therapy
All patients will be discussed in the institutional multidis-
ciplinary tumorboard before discharge. Depending on the
individual tumor stage and postsurgical physical recovery,
adjuvant chemotherapy will be recommended according
to the current national and international guidelines.
Long-term follow up
After completion of the initially recommended tumor-spe-
cific therapy, routine follow up will be performed every
three months up to 24months and includes thoracic and
abdominal sectional imaging as well as lung function
assessment. In addition, translational blood analysis will
be conducted on e.g. tumor markers, peripheral blood
mononuclear cells, antibody profiles and cellular as well
humoral immune-related response parameters. Clinical or
radiological findings suspicious for tumor recurrence will
result in whole body restaging and further individual
examination. The end of the entire trial is defined as the
end of follow up of the last patient included.
Adverse events
An adverse event (AE) is defined in the International Con-
ference on Harmonization (ICH) Guideline for Good
Clinical Practice as “any untoward medical occurrence in
a patient or clinical investigation subject administered a
pharmaceutical product and which does not necessarily
have a causal relationship with this treatment” (ICH E6:
section 1.2). An adverse event can therefore be any un-
favorable and unintended sign (including an abnormal
laboratory finding, for example), symptom, or disease tem-
porally associated with the use of a medicinal (investiga-
tional) product, whether or not considered related to the
medicinal (investigational) product.
A serious adverse event (SAE) is defined as any untoward
medical occurrence (adverse event) that at any dose results
in death, is life-threatening, requires new or prolonged
in-patient hospitalization, results in persistent or significant
disability/incapacity, is a congenital anomaly/birth defect
or, any other significant medical condition.
Progression of the NSCLC and symptoms caused by
progression of the NSCLC need not to be reported as
SAE in this protocol, unless progression or symptoms
of progression are assessed as causally related to study
medication.
Study discontinuation
The whole study will be stopped in the event of any of
the following:
– Medical or ethical reasons affecting the continued
performance of the study
– Occurrence of AEs unknown to date in respect of
their nature, severity, and duration or the
unexpected incidence of known AE with a negative
impact on the risk/benefit assessment
– medically unacceptable risks for the treatment of the
patients
– At the interim analysis (15 patients included): if the
rate of unresectability is equal or greater 20%; i.e. if
3/15 or more study subjects did not undergo surgery
as planned according to the protocol (unresectable
disease or excessive delay of surgery).
Translational research
All patients that are included into the trial will participate
in a translational research program. The standard collec-
tion of specimen includes pre-therapeutic diagnostic bi-
opsy, surgical specimen and sequential blood samples. Of
major interest is the analysis of possible therapy-associated
changes in different tumor regions (eg. Tumor core vs.
marginal zone), the mediastinal and hilar lymph-nodes, the
healthy lung tissue and the peripheral blood. Detailed
research will be conducted to further investigate the tumor
microenvironment, tumor mutational burden, mutational
status, cytokine expression levels and genomic alter-
ations. Further examinations of tumor tissue taken
pre- and post Pembrolizumab will include whole gen-
ome sequencing and FACS-examination of the intra-
tumoral immune infiltrate. Polarization of tumor
associated macrophages (TAMs) in response to anti
PD-1 treatment will be investigated.
Workup of pre- and posttreatment blood will focus on
cytokine−/chemokine-profiles and antibody-profiles using
multiplex assays. Specific interactions between tumor and
immune-cells will be examined by further research on
neo-epitope- specific T-cell responses and T-cell-receptor
-clonality analysis. In order to evaluate a correlation be-
tween the mutational-load/transcriptome of the tumor
and the peripheral blood, whole exome sequencing of cell
free plasma DNA will be performed.
Data of the patients participating in the NEOMUN trial
will be compared to patient data from an institutional
biobank cohort matched to age, gender, stage of disease
and tumor-dependent parameters (histology, size, nodal
status). The matched cohort will only include patients
who did not receive immunomodulatory treatment.
Data analysis
All demographic and clinical characteristics recorded at
baseline will be submitted to descriptive analyses using de-
scriptive statistics by means of listing and tables. Continu-
ous data will be summarized with at least the following:
frequency (n), median, quartiles, mean, standard deviation
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(standard error), minimum and maximum. Statistical test
between changes of parameters over time will be per-
formed for continuous as well as categorical variables.
Wilcoxon signed rank test, Fisher’s exact test and other
appropriate tests will be used where applicable. Time-to-
event measures (OS, DFS) will be analyzed by means of
Kaplan-Meier curves. A p-value of < 0.05 will be consid-
ered statistically significant.
For the analysis of adverse events, summary tables
providing the number and percentage of patients will be
generated for the incidence of AEs overall and by sever-
ity. Laboratory parameters will be reported with descrip-
tive statistics.
Discussion
Patients with NSCLC and nodal N1 and/or N2 disease
suffer from an overall relapse rate of 52% even when
multimodality treatment including curative intent sur-
gery with chemo- and/or radiotherapy is administered.
The overall 5-year survival benefit in these patients
accounts of only 4 to 5% [22, 23]. In terms of efficacy,
no difference between a pre- or postoperative chemo-
therapy approach can be determined [24]. In the light of
the efficacy results it is clear, that new multimodal treat-
ment strategies are direly needed in order to improve
long term survival following curative intent surgery.
Recently, immunotherapies targeting the PD-1/PD-L1
pathway have had significant impact on survival in
patients with advanced stages of NSCLC in comparison
to standard chemotherapy [10]. A correlation between
PD-L1-expression (> 50%) and survival or response to
immunotherapy has been shown in recent anti-PD-1
trials [25, 26]. However, the efficacy of Pembrolizumab
as a first-line treatment in advanced and/or metastatic
NSCLC patients with PD-L1 expression below 50% is
under debate. Based upon preliminary promising results
from the KEYNOTE-trials, the combination of Pembroli-
zumab and pemetrexed/carboplatin chemotherapy has
been recently approved as first-line treatment for meta-
static or advanced NSCLC regardless of the PD-L1 expres-
sion [27]. Further results are eagerly awaited to define
more subgroups that are suitable for anti-PD-1 therapy.
Irrespective of the results in metastatic stage IV patients,
the predictive value of the PD-L1 status might have a dif-
ferent impact in patients with non-metastatic earlier-stage
lung cancer with less tumor burden. This hypothesis is
supported by data recently published by Forde et al. [12].
Their trial (NCT02259621) investigated safety and feasi-
bility of patients with early stage I-IIIa NSCLC treated
neoadjuvantly with 2 doses of nivolumab. Major patho-
logic tumor response (defined as less than 10% viable
tumor cells posttreatment) was observed in 9 of 21 (43%)
resected tumors. Importantly, this tumor response did not
correlate with the pre-treatment PD-L1 status assessed in
tumor biopsies by immunohistochemistry.
Moreover, the techniques used to quantitatively assess
the PDL-1 status in small pre-treatment biopsies are
under critical debate. Several factors contributing to a
false-negative or a false-low PD-L1 status have recently
been identified [28]. From a biological point of view
dynamic induction of PD-L1 expression and an intratu-
moral heterogeneity of PDL-1 expression may result in a
false-negative PD-L1 status and may not be accurately
investigated by small sample biopsies. This is supported
by a comparative study investigating the PD-L1 status in
surgically resected specimens and matched biopsies of
NSCLC patients. The study revealed major discordances
between biopsies and surgical specimens with an overall
discordance rate of 48%. In all cases the biopsy speci-
mens underestimated the PDL-1 status observed on the
whole tissue sample [28]. Due to the points listed above,
the authors believe that the benefit/risk ratio is not in-
fluenced by the pretreatment PDL-1 status and therefore
the inclusion of an all-comers population is justifiable.
The translational study research program will raise the
opportunity to generate further data to elucidate the role
of different PD-L1 expression levels in the context of
neoadjuvant immunotherapy.
In addition to the PD-L1 status analysis, EGFR-mu-
tation and ALK-translocation have been implemented in
routine diagnostics and represent important prognostic
parameters in the era of targeted therapy [29]. A correl-
ation between positive EGFR-mutation and high PD-L1
expression in a historical cohort analysis of surgically
resected NSCLC has been shown by Azuma et al. [30].
Several authors have also reported about rare concomitant
expression of EGFR, ALK and/or PD-L1 and thus they so
far refuted their mutual exclusiveness [31, 32]. Neverthe-
less, the NEOMUN-trial aims to include untreated pa-
tients with stage II/IIIA1–3 NSCLC. According to current
guidelines surgical tumor resection is the primary treat-
ment in this patient cohort. This also accounts for
EGFR or ALK positive tumors. To date, there is no
neoadjuvant or adjuvant EGFR- or ALK-TKI therapy
authorized in this patient cohort. Based on this, the
protocol does not include stratification after EGFR/
ALK- mutation analysis and therefore does not exclude
patients with positive mutations.
The question whether checkpoint blockade should be
performed before or after surgery has been addressed by
Liu et al. in a preclinical breast-cancer model. The authors
reported about an increased tumor specific CD8+ T-cell
response in patients after neoadjuvant immunotherapy
[33]. Pircher et al. observed a reduction of regulatory
T-cells (Tregs) in NSCLC patients that received neoadju-
vant immune-chemotherapy (Cetuximab/Docetaxel/Cis-
platin) before surgical resection [34]. Tregs play a relevant
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role in cancer-associated immune-escape mechanisms as
they suppress cytotoxic T-lymphocytes and natural killer
cells [35]. Taking this into account, it is uncontroversial
that a profound interaction between the tumor and its au-
tologous immune-system is necessary to induce tumor-
specific t-cells to overcome tumor induced tolerance and
to generate and activate T-cell memory. We hypothesize
that the anti-neoplastic immune-stimulatory effect will be
more effective in patients treated prior to tumor resection.
Therefore, neoadjuvant immunotherapy by administration
of anti-PD-1 targeting antibodies is very promising and
has led to unforeseen therapeutic efficacy. The results of a
number of ongoing clinical phase II and III trials address-
ing neoadjuvant immunotherapy before surgery in extra-
thoracic solid cancers are awaited with great interest (e.g.
bladder cancer, melanoma, clinicaltrials.gov).
In NSCLC, clinical data on neoadjuvant immuno-
modulatory treatment is scarce but few encouraging
trials investigating anti-PD-1/PD-L1 checkpoint inhib-
ition prior to surgery for NSCLC patients are currently on-
going (e.g. NCT02938624; NCT03217071; NCT02818920;
NCT02259621). In a first interim analysis, Forde et al.
recently published data on patients with NSCLC receiving
neoadjuvant anti-PD-1 therapy (Nivolumab). They ob-
served a major pathological response (less than 10% viable
tumor cells) in 9 of 20 patients (45%) with neoadjuvant im-
munotherapy. These preliminary data and the results of the
KEYNOTE-trials identified immunotherapy as a promising
strategy in NSCLC treatment [10].
The scope of the enrolled NEOMUN trial is to gener-
ate pilot data on the efficacy, safety and the feasibility of
a neoadjuvant anti-PD-1 immunotherapy with Pembroli-
zumab. The research endeavor will be flanked by a
translational research program to elucidate potential
predictive biomarkers and to investigate the mode of
action of anti PD-1 treatment in NSCLC patients.
Abbreviations
AE: Adverse event; ALK: Anaplastic lymphoma kinase; CD: Cluster of
differentiation; CT: Computed tomography; DFS: Disease free survival;
DNA: Deoxyribonucleic acid; EBUS: Endobronchial ultrasound; ECOG: Eastern
Cooperative Oncology Group; EGF: Epithelial growth factor;
FACS: Fluorescence-activated cell scanning; HBV: Hepatitis b virus;
HCV: Hepatitis c virus; HIV: Human immunodeficiency virus; ICH: International
Conference on Harmonization; iRECIST: (RECIST for immune-based therapeu-
tics); MRI: Magnetic resonance imaging; NCI-CTCAE: National Cancer Institute
Common Terminology Criteria for Adverse Events; NSCLC: Non-small cell
lung cancer; OS: Overall survival; PD1/PD-L1: Programmed death 1 receptor/
−ligand; PET: Position emission tomography; Q3w: Every three weeks;
RECIST: Response Evaluation Criteria In Solid Tumors; SAE: Serious adverse
event; SUV: Standard uptake value; TBB: Transbronchial biopsy;
TBC: Tuberculosis; TBNA: Transbronchial needle aspiration; TNM: Tumor node




The investigator initiated NEOMUN-trial is supported by a grant from the
Oncology Merck Investigator Studies Program (MISP), MSD SHARP & DOHME
GMBH, Germany. The funding source (MISP) had no role in the design of this
study and will not have any role during its execution, analyses, interpretation
of the data, or decision to submit results. The submitted publication of the
NEOMUN trial has been peer reviewed by Sponsor before submission.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
FE, ME and LK have written the manuscript, ME, HH and HW have designed
and set up the study, HB and MT have given advise to the concept of study
medication, FL has given advise for the translational research program. All
authors have read and approved the manuscript.
Ethics approval and consent to participate
The authors declare that they have followed the ethical standards of the
responsible committees on human experimentation:
1. Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Paul-
Ehrlich-Str. 51–59, 63225 Langen, Germany, Phone: + 49 6103 77 0 / Email:
pei@pei.de
2. Ethikkommission der Universität Heidelberg, Alte Glockengießerei 11/1; D-
69115 Heidelberg, + 49 6221 33822–0 / Email: ethikkommission-I@med.uni-
heidelberg.de.
The regulatory committees have declared that all regulatory requirements
are in place to start with the NEOMUN 0316-ASG study. Approvals are
available from the corresponding author on reasonable request.
Written informed consent for scientific analysis of clinical details and/or
associated medical data or study-related results is obtained from the participant




The authors declare that they have no competing interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Thoracic Surgery, Thoraxklinik, Heidelberg University,
Roentgenstraße 1, 69126 Heidelberg, Germany. 2Institute of Pathology,
Heidelberg University, Heidelberg, Germany. 3Divison of Thoracic Surgery,
Technical University of Munich, Munich, Germany. 4Translational Lung
Research Center (TLRC), Member of German Center for Lung Research (DZL),
Heidelberg, Germany. 5Department of Thoracic Oncology, Thoraxklinik,
Heidelberg University, Heidelberg, Germany.
Received: 23 July 2018 Accepted: 18 April 2019
References
1. Miller KD, et al. Cancer treatment and survivorship statistics, 2016. CA
Cancer J Clin. 2016;66(4):271–89.
2. Ferlay J, et al. Cancer incidence and mortality patterns in Europe: estimates
for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
3. Meza R, et al. Lung cancer incidence trends by gender, race and histology
in the United States, 1973-2010. PLoS One. 2015;10(3):e0121323.
4. Morgensztern D, et al. Trends in stage distribution for patients with non-
small cell lung cancer: a National Cancer Database survey. J Thorac Oncol.
2010;5(1):29–33.
5. Goldstraw P, et al. The IASLC lung Cancer staging project: proposals for
revision of the TNM stage groupings in the forthcoming (eighth) edition of
the TNM classification for lung Cancer. J Thorac Oncol. 2016;11(1):39–51.
6. Travis WD, et al. The 2015 World Health Organization classification of lung
tumors: impact of genetic, clinical and radiologic advances since the 2004
classification. J Thorac Oncol. 2015;10(9):1243–60.
7. Goldstraw P, et al. Non-small-cell lung cancer. Lancet. 2011;378(9804):
1727–40.
Eichhorn et al. BMC Cancer          (2019) 19:413 Page 7 of 8
8. Arriagada R, et al. Long-term results of the international adjuvant lung
cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected
lung cancer. J Clin Oncol. 2010;28(1):35–42.
9. Douillard JY, et al. Adjuvant cisplatin and vinorelbine for completely
resected non-small cell lung cancer: subgroup analysis of the lung adjuvant
cisplatin evaluation. J Thorac Oncol. 2010;5(2):220–8.
10. Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a
randomised controlled trial. Lancet. 2016;387(10027):1540–50.
11. Miao L, et al. PD-L1 and c-MET expression and survival in patients with
small cell lung cancer. Oncotarget. 2017;8(33):53978–88.
12. Forde PM, et al. Neoadjuvant PD-1 blockade in Resectable lung Cancer. N
Engl J Med. 2018.
13. Eisenhauer EA, et al. New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
14. Seymour L, et al. iRECIST: guidelines for response criteria for use in trials
testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52.
15. Nishino M, et al. New response evaluation criteria in solid tumors (RECIST)
guidelines for advanced non-small cell lung cancer: comparison with
original RECIST and impact on assessment of tumor response to targeted
therapy. AJR Am J Roentgenol. 2010;195(3):W221–8.
16. Junker K, et al. Grading of tumor regression in non-small cell lung cancer :
morphology and prognosis. Chest. 2001;120(5):1584–91.
17. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions.
Hoboken: Wiley; 2013.
18. Newcombe RG. Two-sided confidence intervals for the single proportion:
comparison of seven methods. Stat Med. 1998;17(8):857–72.
19. Goeckenjan G, et al. Prevention, diagnosis, therapy, and follow-up of lung
cancer. Pneumologie. 2010;64 Suppl 2:e1–164.
20. Goldstraw P, et al. The IASLC lung Cancer staging project: proposals for the
revision of the TNM stage groupings in the forthcoming (seventh) edition
of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):
706–14.
21. Zhong W, et al. Complete mediastinal lymphadenectomy: the core
component of the multidisciplinary therapy in resectable non-small cell
lung cancer. Eur J Cardiothorac Surg. 2008;34(1):187–95.
22. Yamauchi Y, et al. The dynamic pattern of recurrence in curatively resected
non-small cell lung cancer patients: experiences at a single institution. Lung
Cancer. 2015;90(2):224–9.
23. Hanna GG, et al. Preoperative chemotherapy for non-small-cell lung cancer.
Lancet. 2014;384(9939):232–3.
24. McElnay P, Lim E. Adjuvant or neoadjuvant chemotherapy for NSCLC. J
Thorac Dis. 2014;6(Suppl 2):S224–7.
25. Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-
small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–33.
26. Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous
non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627–39.
27. De Lima Lopes G, et al. P2.43: Pembrolizumab vs platinum-based
chemotherapy for PD-L1+ NSCLC: phase 3, randomized, open-label
KEYNOTE-042 (NCT02220894): track: immunotherapy. J Thorac Oncol. 2016;
11(10S):S244–5.
28. Ilie M, et al. Comparative study of the PD-L1 status between surgically
resected specimens and matched biopsies of NSCLC patients reveal major
discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann
Oncol. 2016;27(1):147–53.
29. Janku F, et al. Novel therapeutic targets in non-small cell lung cancer. J
Thorac Oncol. 2011;6(9):1601–12.
30. Azuma K, et al. Association of PD-L1 overexpression with activating EGFR
mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014;
25(10):1935–40.
31. Santelmo C, et al. Coexistence of EGFR mutation and ALK translocation in
NSCLC: literature review and case report of response to gefitinib. Lung
Cancer. 2013;81(2):294–6.
32. Yoneshima Y, et al. PD-L1 expression in lung adenocarcinoma harboring
EGFR mutations or ALK rearrangements. Lung Cancer. 2018;118:36–40.
33. Liu J, et al. Improved efficacy of neoadjuvant compared to adjuvant
immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):
1382–99.
34. Pircher A, et al. Neoadjuvant chemo-immunotherapy modifies CD4(+
)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC)
patients. Lung Cancer. 2014;85(1):81–7.
35. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor
immune escape and angiogenesis. Cancer Res. 2012;72(9):2162–71.
36. Robinson LA, et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3
Suppl):243S–65S.
37. Goeckenjan G, et al. Prevention, diagnosis, therapy, and follow-up of lung
cancer: interdisciplinary guideline of the German respiratory society and the
German Cancer society. Pneumologie. 2011;65(1):39–59.
Eichhorn et al. BMC Cancer          (2019) 19:413 Page 8 of 8
